Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?

Cathie Wood's Ark Invest has significantly increased its position in Beam Therapeutics, a biotech company using base editing technology for genetic treatments. With multiple clinical programs advancing toward FDA approval and sufficient cash runway through mid-2029, Beam could transform into a commercial biotech company. However, the investment remains speculative and dependent on successful clinical trials and regulatory approvals.